SELLAS Life Sciences Announces USPTO Decision to Grant New Patent for Galinpepimut-S in Combination with Checkpoint Inhibitor...
27 May 2021 - 10:30PM
SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the
“Company”), a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapies for a broad range of
indications, today announced that the U.S. Patent and Trademark
Office (USPTO) has issued a Notice of Allowance in a patent
application covering the use of galinpepimut-S (GPS), the Company’s
Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in
combination with checkpoint inhibitor therapies for treatment of
WT1-expressing cancers.
“These new patent claims add to SELLAS’ growing
intellectual property (IP) estate for GPS and continue to support
the Company’s clinical studies of GPS in combination with
checkpoint inhibitors in patients with advanced ovarian cancer and
malignant pleural mesothelioma (MPM) who had exhausted their
current standard therapy options,” said Angelos Stergiou, President
and Chief Executive Officer, SELLAS. “This additional IP protection
for GPS is a major milestone as we look to further advance our
clinical pipeline. We look forward to providing further data from
our study of GPS in combination with pembrolizumab in patients with
2nd or 3rd line relapsed/refractory metastatic ovarian
cancer, as well as the study of GPS in combination with nivolumab
in relapsed/refractory MPM later this quarter.”
The allowed claims of the patent application cover
the use of GPS in combination with any antibody checkpoint
inhibitor that blocks or inhibits programmed cell death protein 1
(PD-1), such as nivolumab and pembrolizumab. The allowed claims of
the patent application also cover treating, reducing the incidence
of, or inducing an immune response against any WT1-expressing
cancer, such as ovarian cancer and MPM.
This patent application covering the use of GPS in
combination with checkpoint inhibitors will be the first granted
within a patent family filed in several countries and will have a
term that extends to at least 2036. The patent application is
expected to be granted on June 15, 2021, as U.S. Patent No.
11,033,613. About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused
on developing novel cancer immunotherapeutics for a broad range of
indications. SELLAS’ lead product candidate, GPS, is licensed from
Memorial Sloan Kettering Cancer Center and targets the WT1 protein,
which is present in an array of tumor types. GPS has potential both
as a monotherapy and in combination to address a broad spectrum of
hematologic malignancies and solid tumor indications. SELLAS’
second product candidate, nelipepimut-S (NPS), is a HER2-directed
cancer immunotherapy with potential to treat patients with
early-stage breast cancer with low to intermediate HER2 expression,
otherwise known as HER2 1+ or 2+, which includes triple negative
breast cancer patients, following the standard of care.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Forward-Looking Statements This
press release contains forward-looking statements. All statements
other than statements of historical facts are “forward-looking
statements,” including those relating to future events. In some
cases, forward-looking statements can be identified by terminology
such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,”
“should,” “project,” “believe,” “estimate,” “predict,” “potential,”
“intend,” or “continue” and other words or terms of similar
meaning. These statements include, without limitation, statements
related to the clinical development and intellectual property
protection of GPS for various cancer indications, including ovarian
cancer and MPM. These forward-looking statements are based on
current plans, objectives, estimates, expectations and intentions,
and inherently involve significant risks and uncertainties. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, risks
and uncertainties associated with the COVID-19 pandemic and its
impact on the Company’s clinical plans, risks and uncertainties
associated with immune-oncology product development and clinical
success thereof, the uncertainty of regulatory approval, and other
risks and uncertainties affecting SELLAS and its development
programs as set forth under the caption “Risk Factors” in SELLAS’
Annual Report on Form 10-K filed on March 23, 2021 and in its other
SEC filings. Other risks and uncertainties of which SELLAS is not
currently aware may also affect SELLAS’ forward-looking statements
and may cause actual results and the timing of events to differ
materially from those anticipated. The forward-looking statements
herein are made only as of the date hereof. SELLAS undertakes no
obligation to update or supplement any forward-looking statements
to reflect actual results, new information, future events, changes
in its expectations or other circumstances that exist after the
date as of which the forward-looking statements were made.
For more information, please
contact:
Investor Contacts Valter Pinto /
Allison Soss KCSA Strategic Communications
Email: SELLAS@kcsa.com Phone: 914.907.2675 / 215.272.2707
Media Contacts Caitlin Kasunich /
Raquel Cona KCSA Strategic Communications
Email: SELLAS@kcsa.com Phone: 212.896.1241 / 212.896.1276
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2024 to May 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From May 2023 to May 2024